Merck sold $3.2 billion of its Covid oral antiviral treatment, driving first-quarter revenue growth

Merck sold .2 billion of its Covid oral antiviral treatment, driving first-quarter revenue growth


Medicine pill is seen with Merck logo and words ‘Molnupiravir’ and ‘COVID-19’ displayed on a screen in the background in this illustration photo taken in Poland on November 5, 2021.

Jakub Porzycki | NurPhoto | Getty Images

Merck sold $3.2 billion of its oral antiviral treatment for Covid in the first quarter, fueling the company’s strong revenue growth.

Merck soundly beat Wall Street profit and revenue forecasts, reporting earnings of $2.14 per share on $15.9 billion in revenue. The company raised its 2022 earnings guidance to between $7.24 and $7.36 per share on $56.9 billion to $58.1 billion in revenue. It previously projected earnings per share between $7.12 to $7.27 on revenue of between $56.1 to $57.6 billion.

Merck’s stock rose nearly 2% in premarket trading.

Here’s how Merck performed compared with what Wall Street expected, based on analysts’ average estimates compiled by Refinitiv:

  • Adjusted earnings: $2.14 per share vs. $1.83 expected
  • Revenue: $15.9 billion vs. $14.68 billion

Merck’s Covid treatment, molnupiravir, has sold well since the Food and Drug Administration authorized the pill in December. It made up 20% of the company’s first-quarter revenue. However, Merck lowered its 2022 sales guidance for molnupiravir to between $5 billion and $5.5 billion, down from its previous outlook of $5 billion to $6 billion. Merck splits profits from the pill equally with its partner Ridgeback Therapeutics.

Overall, pharmaceutical sales grew 50% to $14.1 billion compared to first quarter 2021. Keytruda, an antibody treatment used against several types of cancer, booked sales of $4.8 billion, 23% growth over the same quarter last year. Gardasil, Merck’s HPV vaccine, grew 59% to $1.46 billion compared to 2021.

This is a developing story. Please check back for updates.

CNBC Health & Science

Read CNBC’s latest global coverage of the Covid pandemic:



Source

Starbucks will stop charging extra for dairy substitutes
Business

Starbucks will stop charging extra for dairy substitutes

Starbucks offers oat milk as a dairy-free option. Source: Starbucks Starbucks said Wednesday that it will remove the surcharge for dairy substitutes, saving some U.S. customers more than 10% on their drinks. The change goes into effect Nov. 7 and follows years of pleading from customers to eliminate the extra fee, especially as milk alternatives […]

Read More
Carvana raises 2024 earnings guidance after topping Wall Street’s Q3 expectations
Business

Carvana raises 2024 earnings guidance after topping Wall Street’s Q3 expectations

A Carvana sign and signature vending machine in Tempe, Arizona. Michael Wayland | CNBC Carvana on Wednesday raised its 2024 earnings guidance after the online used-car retailer significantly topped Wall Street’s third-quarter expectations. Here’s how the company performed in the third quarter, compared with average estimates compiled by LSEG: Earnings per share: 64 cents vs. 25 […]

Read More
Starbucks is about to report earnings. Here’s what to expect
Business

Starbucks is about to report earnings. Here’s what to expect

Brian Niccol speaking on CNBC’s Squawk Box on Oct. 30th, 2018.  Anjali Sundaram | CNBC Starbucks is set to share more details about its fiscal fourth quarter after the bell on Wednesday. The coffee giant shared its preliminary quarterly results on Oct. 22, showing that its sales fell for the third consecutive quarter. Here’s what […]

Read More